tirzepatide compounding ban Fifth Circuit probes FDA on compounded GLP-1s The Impact of New FDA

Long-term safety data is still being collected, but clinical trials lasting up to 72 weeks have shown a manageable safety profile

S.TurnbullD

doi: 10.1111/and.2016.48.issue-7 79 AppletonJ

However, a new study, focusing on heart failure, suggests more limited intake

The complexities arise from Section 503A of the Federal Food, Drug, and Cosmetic Act, which relates to the necessary conditions for drug compounding.20 The rules concerning the compounding of therapeutic peptides state that they must come from accredited compounding pharmacies, and the compounded drug must either be compounded from an existing FDA-approved drug product or use drug products included on the 503A bulks list (i.e., the FDAs roster of compoundable substances.)21 But many therapeutic peptides dont satisfy either of the 503A conditions